Ascendis Health said on Friday that its subsidiary, Remedica, had delivered revenue growth of 18% in the year to November driven by the launch of new products.
It said on Friday that Remedica “forms a material part of the company’s de-gearing strategy and continues to perform well and in line with management’s expectations”. Sardi said potential buyers may have sought to take advantage of weakness in the group’s balance sheet to extract value, but Ascendis was intent on getting a fair deal.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Market data — December 30 2019Market data including bonds, unit trusts and fuel prices
출처: BDliveSA - 🏆 12. / 63 더 많은 것을 읽으십시오 »